netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01  Expand sub section  Cytotoxic drugs
 note 

The chemotherapy of cancer is complex and should be confined to specialists in oncologyand haematology. NPSA anti-cancer drug recommendations.

NOTE: a number of cytotoxic medicines that are used for indications other than cancer are listed elsewhere in this formulary under the relevant chapter e.g. methotrexate for rheumatological indications in chapter 10.

Only trained pharmacy personnel should reconstitute cytotoxics and prescription validation should only be carried out by suitably trained pharmacists. 

All cytotoxics with a positive NICE Health Technology Appraisal are approved for use in Greater Manchester.

NHS England's Cancer Drug Fund provides a further list of approved uses of cytotoxic drugs and the latest national funding policies.

08.01  Expand sub section  Side-effects of cytotoxic drugs
08.01  Expand sub section  Drugs for cytotoxic-induced side-effects
08.01.01  Expand sub section  Alkylating drugs
 note 

All cytotoxics with a positive NICE Health Technology Appraisal are approved for use in Greater Manchester. NHS England's Cancer Drug Fund provides a further list of approved uses of cytotoxic drugs and the latest national funding policies.

08.01.02  Expand sub section  Anthracyclines and other cytotoxic antibiotics to top
 note 

All cytotoxics with a positive NICE Health Technology Appraisal are approved for use in Greater Manchester. NHS England's Cancer Drug Fund provides a further list of approved uses of cytotoxic drugs and the latest national funding policies.

08.01.03  Expand sub section  Antimetabolites
 note 

All cytotoxics with a positive NICE Health Technology Appraisal are approved for use in Greater Manchester. NHS England's Cancer Drug Fund provides a further list of approved uses of cytotoxic drugs and the latest national funding policies.

08.01.04  Expand sub section  Vinca alkaloids and etoposide
 note 

All cytotoxics with a positive NICE Health Technology Appraisal are approved for use in Greater Manchester. NHS England's Cancer Drug Fund provides a further list of approved uses of cytotoxic drugs and the latest national funding policies.

08.01.05  Expand sub section  Other antineoplastic drugs
 note 

All cytotoxics with a positive NICE Health Technology Appraisal are approved for use in Greater Manchester. NHS England's Cancer Drug Fund provides a further list of approved uses of cytotoxic drugs and the latest national funding policies.

08.01.05  Expand sub section  Hydroxycarbamide
 ....
 Non Formulary Items
Amifostine  (Ethyol)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Red
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   

Black

These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  

Green

Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  

Grey

Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   

Red

Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.   

netFormulary